# A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

> **NCT00788593** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 82 (actual)

## Conditions studied

- Chronic Pancreatitis
- Exocrine Pancreatic Insufficiency

## Interventions

- **DRUG:** Placebo
- **DRUG:** EUR-1008 (APT-1008) High Dose
- **DRUG:** EUR-1008 (APT-1008) Low Dose

## Key facts

- **NCT ID:** NCT00788593
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00788593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00788593, "A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00788593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*